Search clinical trials for: PF-04360365 1 mg/kg

Total 2112 results

Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Completed

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden
Pfizer

Completed

Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer

Completed

A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Completed

A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Canada, United Kingdom, Australia, Sweden
Pfizer

Completed

Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

Alzheimer's Disease

United States, Sweden
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Bio Sidus SA

Completed

PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion

Fabry Disease

Argentina
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Asthma

United States, Canada
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
AM-Pharma

Completed

Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects

Healthy

Japan
Poitiers University Hospital

Completed

Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

Morbid Obesity

France
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Corvus Pharmaceuticals, Inc.

Terminated

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Covid-19

United States, Colombia, Spain, Canada, Peru, Brazil, Italy, Argentina, Chile, Germany, Mexico, Ukraine
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Active, not recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States
Programme National de Lutte contre l'Onchocercose...

Completed

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients (EOLoa)

Onchocerciasis, Ocular | Loiasis

Congo
Alopexx Pharmaceuticals, LLC

Terminated

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

Neisseria Gonorrhoeae

United States
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
Alexion Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD) | LAL-Deficiency

France, United States, United Kingdom, Czechia
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
NoNO Inc.
University of Calgary

Completed

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)

Stroke, Acute

United States, Ireland, Korea, Republic of, Canada, Sweden, Germany, United Kingdom, Australia
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Completed

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Dyslipidemia | Hypercholesterolemia

United States
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Centocor, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

United States, Canada, Netherlands, Belgium, Germany
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
MedImmune LLC
PRA Health Sciences; Cambridge Antibody Technology

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma

Asthma

Netherlands, United Kingdom, Australia, Germany, Poland
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States

3

Subscribe